ReviewInternational journal of molecular sciences2018
Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Adropin, S100A1, and SERCA2b Dysregulation in Coronary Artery Disease: Molecular and In Silico Insights into Calcium Signaling and Metabolic Dysfunction.Biomedicines · 2026Article
- Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice.Nature communications · 2026Article
- The Landscape of SERCA2 in Cardiovascular Diseases: Expression Regulation, Therapeutic Applications, and Emerging Roles.Biomolecules · 2026Review
- Aberrant myocardial calcium cycling: pathogenic mechanisms and targeted therapeutics for heart failure.Frontiers in cardiovascular medicine · 2026Review
- DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.Circulation research · 2025Article
- Integrated analysis of gene networks and cellular functions identifies novel heart failure biomarkers.Hereditas · 2025Article
- PAD2 disturbs cardiomyocyte calcium homeostasis by citrullinating SERCA2a protein in hemorrhagic shock induced arrhythmia.The journal of trauma and acute care surgery · 2025Article
- SERCA2a dysfunction in the pathophysiology of heart failure with preserved ejection fraction: a direct role is yet to be established.Heart failure reviews · 2025Review
- Intracellular calcium channels: Potential targets for type 2 diabetes mellitus?World journal of diabetes · 2025Review
- AI-driven automated discovery tools reveal diverse behavioral competencies of biological networks.eLife · 2025Article
- Gene therapy for polygenic or complex diseases.Biomarker research · 2024Review
- Intermittent Hypoxic Preconditioning Plays a Cardioprotective Role in Doxorubicin-Induced Cardiomyopathy.Cardiovascular toxicology · 2023Article
- Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure.International journal of molecular sciences · 2022Review
- Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors.Frontiers in pharmacology · 2022Review
- Role of Posttranslational Modifications of Proteins in Cardiovascular Disease.Oxidative medicine and cellular longevity · 2022Review
- The Function of SUMOylation and Its Critical Roles in Cardiovascular Diseases and Potential Clinical Implications.International journal of molecular sciences · 2021Review
- Mitochondrial Bioenergetics and Dynamism in the Failing Heart.Life (Basel, Switzerland) · 2021Review
- Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection.Current heart failure reports · 2021Review
- Mitochondrial Homeostasis Mediates Lipotoxicity in the Failing Myocardium.International journal of molecular sciences · 2021Review
- Potential roles of mediator Complex Subunit 13 in Cardiac Diseases.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic heart failure (CHF) is a major contributor to cardiovascular disease and is the leading cause of hospitalization for those over the age of 65, which is estimated to account for close to seventy billion dollars in healthcare costs by 2030 in the US alone. The successful therapies for preventing and reversing CHF progression are urgently required. One strategy under active investigation is to restore dysregulated myocardial calcium (Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.